<table>
<thead>
<tr>
<th>Title</th>
<th>Materials And Methods For Treatment Of Liver Cancer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inventor(s)</td>
<td>Cheung, ST; Fan, ST; Cheung, PFY</td>
</tr>
<tr>
<td>Citation</td>
<td>US Published patent application US 20140356321. Washington, DC: US Patent and Trademark Office (USPTO), 2014</td>
</tr>
<tr>
<td>Issued Date</td>
<td>2014</td>
</tr>
<tr>
<td>URL</td>
<td><a href="http://hdl.handle.net/10722/208124">http://hdl.handle.net/10722/208124</a></td>
</tr>
<tr>
<td>Rights</td>
<td>This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.</td>
</tr>
</tbody>
</table>
**United States**

**Patent Application Publication**

**Publication Classification**

- **Int. Cl.**
  - C07K 16/22 (2006.01)
  - A61K 45/06 (2006.01)
  - C12N 15/113 (2006.01)

- **U.S. Cl.**
  - CPC ................ C07K 16/22 (2013.01); C12N 15/113 (2013.01); A61K 45/06 (2013.01); A61K 2039/303 (2013.01)
  - USPC ... 424/85.2; 424/85.4; 424/145.1; 424/158.1; 424/93.71; 514/44 A; 514/54

**ABSTRACT**

Granulin-epithelin precursor (GEP), a pluripotent growth factor, is a hepatic oncofetal protein defining a cancer stem cell (CSC) population in liver cancer. The present invention provides the use of GEP inhibitors (including anti-GEP antibody) for inhibiting immune evasion by liver cancer cells and for eliminating liver cancer stem cells.
Fig. 1 cont.

![Graphs showing cell cytotoxicity for Hep3B and HepG2](image)
Fig. 2

A Cell surface MICA

B Cell surface HLA-E

C Soluble MICA

D Cell surface NKG2D
Fig. 3

A

- **GEP**
  - IgG: 63.8%
  - Control: 55.0%
  - A23: 36.8%

- **Cell surface MICA**
  - Control: 86.8%
  - IgG: 67.4%
  - A23: 80.2%

- **Cell surface HLA-E**
  - A23: 7.7%
  - Control: 19.3%
  - IgG: 16.9%

B

<table>
<thead>
<tr>
<th></th>
<th>Control</th>
<th>A23 treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>IgG</strong></td>
<td><img src="IgG_Control" alt="Image" /></td>
<td><img src="IgG_A23" alt="Image" /></td>
</tr>
<tr>
<td><strong>GEP</strong></td>
<td><img src="GEP_Control" alt="Image" /></td>
<td><img src="GEP_A23" alt="Image" /></td>
</tr>
<tr>
<td><strong>MICA</strong></td>
<td><img src="MICA_Control" alt="Image" /></td>
<td><img src="MICA_A23" alt="Image" /></td>
</tr>
</tbody>
</table>
Fig. 4

A  Effector cells: PBMC

B  Effector cells: NK
Fig. 5

A

B

HCC

IgG

GEP

IgG

MICA

IgG

HLA-E

Non-Tumor

Non-Tumor

Non-Tumor

C

D

<table>
<thead>
<tr>
<th>GEP+ (%)</th>
<th>MICA+ (%)</th>
<th>GEP+ MICA+ (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>4.1 ± 0.3</td>
<td>3.4 ± 1.3</td>
<td>0.5 ± 0.2</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>GEP+ (%)</th>
<th>MICA+ (%)</th>
<th>GEP+ HLA-E+ (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>4.7 ± 1.8</td>
<td>3.8 ± 2.1</td>
<td>3.3 ± 2.1</td>
</tr>
</tbody>
</table>
FIG. 7

A. All patients

B. Early stage

C. Late stage

Recurrence-free Survival (%) vs Years

sGEP/sMICA low

sGEP/sMICA high
FIG. 8

A  Hep3B
Cell surface HLA-G
- GEP suppression: 4.1%
- Control: 4.8%

Cell surface HLA-A/B/C
- GEP suppression: 87.5%
- Control: 90.8%

B  HepG2
Cell surface HLA-G
- GEP over-expression: 1.2%
- Control: 0.7%

Cell surface HLA-A/B/C
- GEP over-expression: 98.1%
- Control: 93.8%
MATERIALS AND METHODS FOR
TREATMENT OF LIVER CANCER

CROSS-REFERENCE TO RELATED
APPLICATION

[0001] This application claims the benefit of U.S. provi-
sional application Ser. No. 61/829,027, filed May 30, 2013,
which is herein incorporated by reference in its entirety.

BACKGROUND OF THE INVENTION

[0002] Liver cancer is the third leading cancer killer in
the world, with more than half a million individuals dying
globally each year. In China, liver cancer is the second major
cause of cancer death. Surgical resection, in the form of a
partial hepatectomy or a liver transplant, is the mainstay
curative treatment. Nonetheless, cancer recurrence is still
common after curative surgery. In addition, liver cancer is
frequently diagnosed at an advanced stage, which precludes
curative treatment. No effective therapeutic option exists for
the treatment of the majority of liver cancer patients.

[0003] Granulin-epithelin precursor (GEP) is a pluripotent
growth factor regulating fetal development, tissue repair
and tumorigenesis in various cancers. GEP is over-expressed
in more than 70% of human hepatocellular carcinoma (HCC).
GEP expression has been shown to associate with aggressive
HCC features. Functional studies demonstrate that GEP plays
a role in regulating HCC cell proliferation, invasion, tumori-
genicity, and chemoresistance. Moreover, neutralization of
GEP could inhibit the growth of established HCC in mouse
model.

[0004] Cancer stem cells (CSCs) are considered as the
“root” of cancers. CSCs are not only responsible for tumor
initiation and progression, but also endowed with stem cell
properties, including self-renewal, differentiation capacity
and chemoresistance. Although existing therapies can ini-
tially eliminate the tumor bulk, stem cell properties of CSCs
enable them to survive and repopulate the tumor, resulting in
disease relapse. Thus, CSC eradication may be the key for
curing aggressive malignancies including HCC.

[0005] The immune system has the ability to identify and
eliminate tumor cells before they develop into malignancy.
NK cells are the major component of the innate immune
system and represent the first line of defense against tumors.
Anti-tumor cytotoxicity of NK cells is mediated by direct
lysis or induction of IFN-γ. However, it was reported that
cytotoxicity of NK cells was impaired in HCC patients and
the reduced activities of NK cells are associated with HCC
progression.

[0006] NK cytotoxicity is regulated through integrated sig-
naling from their cell surface receptors that interact with
ligands expressed on target cells. NKGD2 (natural killer
group 2, member D) is a stimulatory receptor expressed
on the surface of all NK cells and its recognition is crucial for
tumor immunosurveillance. MIC class I chain-related mol-
ecule A (MICA), a ligand of human NKGD2 receptor, is
frequently expressed in tumors, but not in normal tissues.
Engagement of MICA and NKGD2 strongly activates NK
cells, enhancing their cytotoxicity and cytokine production.
Thus, the NKGD2-MICA pathway is an important mecha-

nism by which host immune system recognizes and elimi-
nates tumor cells. CD94/NKG2A is an inhibitory receptor
that controls the activity of human NK cells following inter-
actions with the non-classic class I human leukocyte antigen
E (HLA-E) on target cells. HLA-E is ubiquitously expressed
by nearly all cells in the body, but is over-expressed by tumor
cells and is likely to protect the tumor cells from NK cyto-
toxic activity through inhibition via interactions with the CD94/
NKG2A receptor.

[0007] Immune evasion is one of the important properties
of CSCs that enable them to survive better in the host.
Recently, ABCB5+ malignant melanoma initiating cells were
found to possess the capacity to modulate anti-tumor immu-
nity by preferentially inhibiting IL-2-dependent T-cell acti-
vation and to support induction of regulatory T cells. More-
over, CD200+ CSC cells were found to suppress anti-tumor
immunity by down-regulating the expression of Th1 cytoki-
nes and co-stimulatory molecules in ovary cancer, melan-
oma and leukemia. However, evaluation of CSCs in the
context of host immune responses has largely been dis-
regarded in HCC. Therapeutic regimes that inhibit tumor cells
from escaping from immunosurveillance can be used to treat
hepatic CSCs.

BRIEF SUMMARY OF THE INVENTION

[0008] The present invention provides a method for sup-
pressing immune evasion and for eradicating GEP-express-
ing CSCs in hepatocellular carcinoma (HCC). The present
invention is based on the surprising discovery that granulin-
epithelin precursor (GEP) expression is associated with the
immune evasion ability of human liver cancer; GEP is asso-
ciated with the natural killer (NK) cell activity in human liver
cancer; and anti-GEP antibody treatment enhances the NK
cell cytotoxic activities against liver cancer cells.

[0009] In one embodiment, the present invention provides a
method for treating liver cancer, wherein the method com-
prises administering to a subject in need of such treatment
an agent that inhibits the expression of or activity of granulin-
epithelin precursor (GEP) and, optionally, NK cells and/or an
agent that promotes natural killer (NK) cell activity.

[0010] In one embodiment, the agent that promotes NK cell
activity enhances cytotoxicity of NK cells.

[0011] In one specific embodiment, the present invention
provides a method for treating liver cancer, wherein the
method comprises administering to a subject in need of such
treatment an antibody that binds to granulin-epithelin precu-
or (GEP) and, optionally, NK cells and/or an agent that
promotes natural killer (NK) cell activity.

[0012] In one embodiment, the subject has undergone par-
tial or total hepatectomy and/or liver transplantation, and
the present invention can be used to prevent or reduce the likeli-
hood of liver tumor or cancer recurrence.

BRIEF DESCRIPTION OF THE DRAWINGS

[0013] FIG. 1 shows that GEP expression of HCC cells
modulates anti-tumor cytotoxic activity of immune cells. (A)
GEP modulation by transfection in HCC cell lines. GEP
protein and transcript levels were significantly suppressed
in Hep3B (high endogenous GEP cell line, left panel); while
significantly over-expressed in HepG2 (low endogenous GEP
cell line, right panel). GEP protein level was expressed as
MFI (Mean fluorescence intensity), after subtracting that of
isotype control. (B) GEP suppression increased, while over-
expression decreased PBMC cytotoxicity against HCC cells.
HCC cells (target cells) were co-cultured with PBMC (effec-
tor cells) at effector/target ratio (E:T ratio) of 25:1 for 5 h.
*p<0.05 when compared GEP transfectants with control.
cells. (C) Depletion of NK cells markedly abolished the GEP-mediated cell cytotoxicity. CD56+ NK cells were depleted from PBMC by magnetic sorting. NK cells-depleted PBMC were then co-cultured with HCC cells at E:T ratio of 25:1 for 5 h. (D) GEP suppression increased, while over-expression decreased NK cytotoxicity against HCC cells. *p<0.05, **p<0.01 when compared with control cells at respective E:T ratio. NK cells were also isolated from liver cancer patients and cytotoxicity against liver cancer cells analyzed, and (E) the cells showed enhanced cytotoxicity in liver cancer cells with GEP over-expression, and (F) decreased cytotoxicity in liver cancer cells with GEP over-expression.

[0014] FIG. 2 shows that GEP differentially regulates the expression of MICA and HLA-E of HCC cells and NKG2d on NK cells. (A) GEP suppression up-regulated, while over-expression down-regulated surface MICA on HCC cells. MFI: mean fluorescence intensity (after subtracting that of isotype control). (B) GEP suppression down-regulated, while over-expression up-regulated surface HLA-E on HCC cells. MFI: mean fluorescence intensity (after subtracting that of isotype control). (C) GEP suppression reduced, while over-expression augmented soluble MICA release from HCC cells. (D) Co-culture of GEP-suppressed HCC cells increased, while GEP-over-expressed HCC cells decreased NKG2D expression on NK cell surface. Dotted line in histogram: isotype control staining MFI: mean fluorescence intensity (after subtracting that of isotype control). * p<0.05, **p<0.01, ***p<0.001 when compared with control cells.

[0015] FIG. 3 shows that GEP blockage by anti-GEP antibody A23 mediates the expression of MICA and HLA-E of HCC cells. Hep3B cells were treated with anti-GEP antibody (A23), mouse IgG isotype (IgG) (50 µg/ml) or without antibody (control) in serum-starved condition (1% FBS) for 24 h. (A) A23 significantly reduced GEP expression of Hep3B cells. A23 induced cell surface MICA expression, while suppressed soluble MICA release and cell surface HLA-E expression of Hep3B cells. Dotted line: isotype control staining. * p<0.05, ** p<0.01 when compared with control. MFI: mean fluorescence intensity (after subtracting that of isotype control). (B) Orthotopic tumors of Hep3B cells were established in nude mice, which were then subjected to saline (control) or 10 mg/kg anti-GEP antibody A23 (A23 treatment) twice weekly for six weeks. Tumors were stained by immunohistochemistry for GEP and MICA proteins.

[0016] FIG. 4 shows that GEP blockage by anti-GEP antibody A23 enhances NK cell cytotoxicity against HCC cells via MICA. Hep3B and HepG2 cells were treated with anti-GEP monoclonal antibody (A23), mouse IgG isotype control (IgG) (50 µg/ml) or without antibody (control) in serum-starved condition (1% FBS) for 24 h prior to co-culture with PBMC at E:T ratio of 25:1 for 5 h. For A23 treatment, cells were co-cultured with PBMC with or without neutralizing MICA antibody (anti-MICA) or mouse IgG2a isotype control (IgG2a) (2 µg/ml) for 5 h. (A) GEP blockage by anti-GEP antibody A23 enhanced PBMC cytotoxicity against HCC cells. The cytotoxicity is suppressed by anti-MICA neutralizing antibody. *p<0.05 when compared with control; #p<0.05 between groups denoted by horizontal lines. (B) A23-enhanced NK cytotoxicity against Hep3B and HepG2 cells was suppressed by anti-MICA neutralizing antibody. * p<0.05, ** p<0.01, ***p<0.001 when compared with A23 alone treatment at respective E:T ratio.

[0017] FIG. 5 shows the expression patterns of GEP, MICA and HLA-E in HCC clinical specimens. (A) GEP, MICA and HLA-E mRNA levels were up-regulated in HCC compared with the paralleled adjacent non-tumor liver tissues and normal livers from healthy individuals (p<0.001, p<0.000 and p<0.089, respectively). (B) Immunohistochemical staining showed stronger expression of GEP, MICA and HLA-E proteins in HCC than the paralleled adjacent non-tumor liver tissues. (C) Serum GEP (sGEP) and MICA (sMICA) levels were significantly higher in HCC patients than those of healthy individuals (p<0.01 and p<0.001, respectively). (D) Liver tissues were digested into disaggregated cells, and assessed for the expression of surface MICA, HLA-E and GEP. Expressions of surface MICA and GEP were mutually exclusive (left panel). Surface HLA-E co-expressed with GEP (right panel). Table summarizes the mean percentage of positive cells±SD from 3 HCC clinical specimens respectively.

[0018] FIG. 6 shows antibody-dependent cellular cytotoxicity mediated by anti-GEP monoclonal antibody A23, A23-mediated ADCC against HCC cells dose-dependently. Hep3B or HepG2 cells labeled with CFSE were incubated with or without anti-GEP antibody A23 (A23) or mouse isotype control (mIgG) of the indicated concentrations of the antibodies for 30 min prior to co-culture with or without PBMC at E:T ratio of 25:1 for 5 h. * p<0.05, ** p<0.01 when compared with control cells without antibody. (B) Depletion of CD56+ NK cells from human PBMC markedly abolished A23-mediated ADCC. Hep3B or HepG2 cells labeled with CFSE were incubated with or without anti-GEP antibody A23 of indicated concentrations for 30 min prior to co-culture with PBMC or NK cell-depleted PBMC at E:T ratio of 25:1 for 5 h. * p<0.05, ** p<0.01 when compared with control cells without antibody. (C) A23-mediated ADCC against HCC cells was dependent on NK cells. CD56+ NK cells were isolated and cultured with HCC cells for 5 h at indicated E:T ratio. *p<0.05, ***p<0.001, ****p<0.0001 when compared with control cells without antibody.

[0019] FIG. 7 shows association of serum GEP and MICA levels with recurrence-free survival in HCC patients. Kaplan-Meier recurrence-free survival plot according to serum GEP (sGEP) and MICA (sMICA) levels. Patients were segregated into low expression group (low in both sGEP and sMICA) and high expression group (either one or both high in sGEP and sMICA) with the Youden index maximized to determine the optimal cutoff value. There were 25 patients in the low expression group (median recurrence-free survival, 51.2 months) and 55 patients in the high expression group (median recurrence-free survival, 12.8 months). (A) Patients with high expression levels of sGEP and/or sMICA (sGEP/sMICA high) were found to have poor recurrence-free survival (log-rank test, p=0.042). When the patients were segregated into (B) early and (C) advanced tumor stages, patients with high sGEP and/or sMICA (sGEP/sMICA high) were also shown to have poor recurrence-free survival (log-rank test, p=0.032).

[0020] FIG. 8 shows that GEP does not regulate the expression of HLA-G and HLA-A/B/C of HCC cells. (A) Hep3B cells (high endogenous GEP cell line) were stably transfected for GEP suppression by shRNA, while (B) HepG2 cells (low endogenous GEP cell line) were stably transfected for over-expression by full-length GEP cDNA. Surface HLA-G and HLA-A/B/C expression on the HCC cells and their GEP
transfectants was measured by surface immunofluorescence staining and flow cytometry. Dotted line: isotype control staining.

BRIEF DESCRIPTION OF THE SEQUENCES

[0021] SEQ ID NO:1 is a cDNA sequence of a granulin-epithelin precursor (GEP).
[0022] SEQ ID NO:2 is the amino acid sequence of a granulin-epithelin precursor.
[0023] SEQ ID NO:3 is the amino acid sequence of part of GEP (GEP amino acids 578-593).
[0024] SEQ ID NO:4 is the nucleic acid sequence encoding amino acids 578-593 of GEP.
[0025] SEQ ID NO:5 is the amino acid sequence of part of GEP (GEP amino acids 351-365).
[0026] SEQ ID NO:6 is the nucleic acid sequence encoding amino acids 351-365 of GEP.
[0027] SEQ ID NO:7 is the amino acid sequence of part of GEP (GEP amino acids 574-593).
[0028] SEQ ID NO:8 is the nucleic acid sequence encoding amino acids 574-593 of GEP.
[0029] SEQ ID NO:9 is the amino acid sequence of part of GEP (GEP amino acids 337-363).
[0030] SEQ ID NO:10 is the nucleic acid sequence encoding amino acids 337-363 of GEP.
[0031] SEQ ID NO:11 is the amino acid sequence of part of GEP signaling peptide (GEP amino acids 1-17).
[0032] SEQ ID NO:12 is the nucleic acid sequence encoding amino acids 1-17 of GEP.
[0033] SEQ ID NO:13 is the amino acid sequence of part of the GEP linker (GEP amino acids 18-57).
[0034] SEQ ID NO:14 is the nucleic acid sequence encoding amino acids 18-57 of GEP.
[0035] SEQ ID NO:15 is the amino acid sequence of part of the GEP linker (GEP amino acids 114-122).
[0036] SEQ ID NO:16 is the nucleic acid sequence encoding amino acids 114-122 of GEP.
[0037] SEQ ID NO:17 is the amino acid sequence of part of the GEP linker (GEP amino acids 180-205).
[0038] SEQ ID NO:18 is the nucleic acid sequence encoding amino acids 180-205 of GEP.
[0039] SEQ ID NO:19 is the amino acid sequence of part of the GEP linker (GEP amino acids 262-280).
[0040] SEQ ID NO:20 is the nucleic acid sequence encoding amino acids 262-280 of GEP.
[0041] SEQ ID NO:21 is the amino acid sequence of part of the GEP linker (GEP amino acids 418-441).
[0042] SEQ ID NO:22 is the nucleic acid sequence encoding amino acids 418-441 of GEP.
[0043] SEQ ID NO:23 is the amino acid sequence of part of the GEP linker (GEP amino acids 497-517).
[0044] SEQ ID NO:24 is the nucleic acid sequence encoding amino acids 497-517 of GEP.

DETAILED DESCRIPTION OF THE INVENTION

[0045] The present invention provides a method for suppressing immune evasion and for eradinating the GEP-expressing CSCs in hepatocellular carcinoma (HCC). The present invention is based on the surprising discovery that granulin-epithelin precursor (GEP) expression is associated with the immune evasion ability of human liver cancer; GEP is associated with the natural killer (NK) cell activity in human liver cancer; and anti-GEP antibody treatment enhances the NK cell cytotoxic activities against liver cancer cells.

Effect of GEP on Immune Evasion and Cancer Stem Cell Population

[0046] The present invention shows that granulin-epithelin precursor (GEP) rendered hepatocellular carcinoma (HCC) cells resistant to cytotoxic activity of NK cells, an important mechanism of anti-tumor responses. The alteration in immune response induced by GEP would cause an imbalance in the host’s immune responses, allowing the subsequent growth of a tumor. Thus, GEP provides a selective advantage to cancer stem cells (CSCs) by enabling them to proliferate in hosts.

[0047] GEP blockage by monoclonal antibody A23 significantly suppresses GEP level in HCC cells, and the GEP-mediated regulation on MICA class I chain-related molecule A (MICA) and HLA-E expression on HCC cells could be reversed. As a result, the HCC cells can be sensitized to NK cytotoxic activity. In addition, the present invention shows that anti-GEP monoclonal antibody A23 induces NK cell-mediated ADCC against HCC cells, and therefore further amplifies the anti-tumor response of the antibody. Therefore, targeting antibody that binds specific to GEP (such as A23 antibody) can be used for suppressing immune evasion and eradicating the GEP-expressing CSCs in HCC.

[0048] GEP defines a hepatic CSC population with greater chemoresistance, self-renewal and tumor-initiating ability. The present inventors discovered that GEP conferred the CSCs’ ability to escape from NK immunosurveillance, giving a selective advantage to the GEP+ cells and enabling them to survive and proliferate in the host.

[0049] As a hallmark of tumor progression and recurrence, tumors have developed diverse mechanisms to evade the immune system. It is postulated that tumor cells have evolved to down-regulate their surface MICA by proteolytic shedding, therefore reducing their susceptibility to NKGD2-mediated NK cytotoxicity. Also, the soluble MICA (sMICA) released from tumor cell surface can not only block the NKGD2-binding site for other NKGD2 ligands, but also suppress NKGD2 expression on NK cells. Production of sMICA therefore represents one of the mechanisms in tumor immune evasion. It was reported that sMICA were frequently elevated in advanced HCC patients and such elevation was associated with down-regulated NKGD2 expression and impaired NK cell activation in HCC. Significance of sMICA as predictive and prognostic marker has been reported in HBV-induced HCC and advanced HCC.

[0050] The present invention shows that GEP suppression significantly up-regulated, while GEP over-expression reduced surface MICA level on HCC cells. GEP-expressing cells might therefore evade NK cytotoxicity by reducing surface MICA level and become less susceptible to NK cell responses. In addition, sMICA level decreased significantly in the culture supernatant of GEP-suppressed HCC cells, but increased significantly when GEP was over-expressed. The results show that GEP could confer HCC cells immune evasion ability by promoting shedding of MICA from cell surface and promote the release of sMICA which disturbs the NKGD2-mediated NK cytotoxicity.

[0051] Up-regulation of HLA-E, a ligand for the NK inhibitory immunoreceptor CD94/NKG2A9, has been suggested to represent a mechanism of tumor escape from NK cell immu-
nosurveillance in ovarian cancer and melanoma. It was previously reported that HLA-E mRNA was up-regulated in HCC specimens in comparison with their adjacent normal counterpart. Also, HLA-E polymorphism was also associated with risk of hepatitis B or HCC.
[0052] Nevertheless, before the present invention, the role of HLA-E in HCC pathogenesis has not been reported. In addition, it was not elucidated that HCC cells over-express HLA-E.
[0053] The present invention shows that GEP expression up-regulated HCC cells’ surface expression of HLA-E, which interacts with NK cell inhibitory immunoreceptor CD94/NKG2A and suppresses NK cell activity.
[0054] HLA-E could play a role in HCC pathogenesis by promoting the immune evasion ability of GEP-expressing CSCs. GEP blockade using anti-GEP monoclonal antibody A23 could significantly suppress GEP level and sensitize the GEP+ cells to NK cytotoxic activity. The results show that antibodies that bind to GEP have antitumor effect against HCC cells once NK cells are efficiently activated during A23 treatment. The combination therapy of anti-HCC molecular targeted therapy and immunotherapy targeting activation of NK cells could improve the antitumor effect against unreseetable HCC and the prognosis of patients with HCC. Also, as the present inventors have shown that GEP expression would induce shedding of MICA from HCC cell surface and increase soluble MICA, patients with higher soluble MICA level in their serum would be more responsive to the anti-GEP monoclonal antibody treatment. The present invention can be used to define criteria to select patients who are potentially responsive to anti-GEP antibody treatment.
[0055] In addition to immune escape, another immunologic mechanism known to play a role in the anti-tumor activity of antibodies is their ability to induce antibody-dependent cell-mediated cytotoxic activity (ADCC) mediated by cytotoxic immune cells (such as NK cells) to lyse the tumor cells. ADCC is an innate immune effector mechanism in which antibodies evoke tumor cell death when antibodies bind to antigen on tumor cells and the antibody Fc domains engage Fc receptors on the surface of immune effector cells.
[0056] The present invention shows that anti-GEP monoclonal antibody A23 could induce NK cell-mediated ADCC against HCC cells. Therefore, the anti-tumor effect of anti-GEP monoclonal antibody A23 can be further amplified by inducing destruction of the A23-coated HCC cells by NK cells. Targeting GEP by antibody A23 represents a novel therapeutic tool for suppressing immune evasion and for eradicating the GEP-expressing CSCs in HCC.

Liver Cancer or Tumor Therapy

[0057] In one embodiment, the present invention provides a method for treating liver cancer, wherein the method comprises administering to a subject in need of such treatment an effective amount of an agent that inhibits the expression or activity of granulin-epithelin precursor (GEP) and, optionally, natural killer (NK) cells and/or an agent that promotes natural killer (NK) cell activity.
[0058] In one embodiment, the agent that promotes NK cell activity enhances cytotoxicity of NK cells.
[0059] In one specific embodiment, the present invention provides a method for treating liver cancer, wherein the method comprises administering to a subject in need of such treatment an antibody that binds to granulin-epithelin precursors (GEP) and, optionally, NK cells and/or an agent that promotes natural killer (NK) cell activity.

[0060] In another specific embodiment, the present invention provides a method for treating liver cancer, wherein the method comprises administering to a subject in need of such treatment a GEP antisense polynucleotide and, optionally, NK cells and/or an agent that promotes natural killer (NK) cell activity. In one specific embodiment, the GEP antisense polynucleotide is administered to a liver tumor of the subject.

[0061] In one embodiment, the agent that inhibits the expression or activity of granulin-epithelin precursor (GEP) is administered before, during, or after NK cells and/or an agent that promotes NK cell activity. In one embodiment, the method comprises administering a therapeutic composition comprising an agent that inhibits the expression or activity of granulin-epithelin precursor (GEP), NK cells, and/or an agent that promotes NK cell activity.

[0062] In another embodiment, the present invention provides a method of treating liver cancer comprising administering to a subject in need of such treatment an effective amount of an agent that increases MHC class I chain-related molecule A (MICA) expression on liver cancer cells. Such agents can be agents that inhibit the activity of GEP, thereby causing an increase in MICA expression on liver cancer cells.

[0063] In yet another embodiment, the present invention provides a method of treating liver cancer comprising administering to a subject that has liver cancer an effective amount of an agent that promotes natural killer (NK) cell activity and/or enhances the cytotoxicity of NK cells, such as GEP inhibiting agents.

[0064] The term “treatment” or any grammatical variation thereof (e.g., treat, treating, and treatment etc.), as used herein, includes but is not limited to, ameliorating or alleviating a symptom of a disease or condition, reducing, suppressing, inhibiting, lessening, or affecting the progression, severity, and/or scope of a condition.

[0065] The term “prevention” or any grammatical variation thereof (e.g., prevent, preventing, and prevention etc.), as used herein, includes but is not limited to, reducing the likelihood of developing a disease, delaying the onset of symptoms, preventing relapse to a disease, increasing latency between symptomatic episodes, or a combination thereof. Prevention, as used herein, does not require the complete absence of symptoms.

[0066] The term “effective amount,” as used herein, refers to an amount that is capable of treating or ameliorating a disease or condition or otherwise capable of producing an intended therapeutic effect.

[0067] The term “subject,” as used herein, describes an organism, including mammals such as primates, to which treatment with the compositions according to the subject invention can be provided. Mammalian species that can benefit from the disclosed methods of treatment include, but are not limited to, apes, chimpanzees, orangutans, humans, monkeys; and other animals such as dogs, cats, horses, cattle, pigs, sheep, goats, chickens, mice, rats, guinea pigs, and hamsters. In one embodiment, the subject has, or is diagnosed with, liver tumor or cancer. In one embodiment, the subject had undergone partial or total hepatectomy and/or liver transplantation.

[0068] The term “partial hepatectomy,” refers to the surgical resection of less than the entire, but more than 5% (including, any percent higher than 5%, including but not limited to,
more than 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, or 95%) of the liver.

[0069] In one embodiment, the present invention can be used to eliminate or reduce liver cancer stem cells. In one embodiment, the administration of one or more GEP inhibitors (such as, anti-GEP antibody) to a subject who had surgical resection of a primary liver tumor can be used to prevent the recurrence of liver tumor or cancer. In one embodiment, the administration of one or more GEP inhibitors (such as, anti-GEP antibody or aptamer) to a subject who had surgical resection of a primary liver tumor can be used to treat liver tumor or cancer.

[0070] In one embodiment, one or more GEP inhibitors (such as, anti-GEP antibody or aptamer) to a subject who had partial hepatectomy or liver transplantation. In one embodiment, the present invention can be used to prevent or reduce the likelihood of liver tumor or cancer recurrence.

[0071] In one embodiment, the subject has undergone surgical resection of an entire primary liver tumor. In one embodiment, the subject has undergone surgical resection of part of a primary liver tumor.

[0072] In one embodiment, one or more GEP inhibitors are administered before or after the subject receives surgical resection of the liver tumor.


GEP Inhibitors

[0074] GEP inhibitors useful according to the present invention include, but are not limited to, agents that inhibit GEP activity; and agents that reduce or inhibit the expression of GEP, such as agents that inhibit the transcription and/or translation of GEP.

[0075] Agents that inhibit GEP activity include, but are not limited to, anti-GEP antibodies, aptamers, GEP binding partners, and small molecule inhibitors of GEP.

[0076] In one embodiment, the GEP inhibitor is an antibody, aptamer, or binding partner that binds to GEP. In a specific embodiment, the GEP inhibitor is an antibody, aptamer, or binding partner that binds specifically to GEP. In a further specific embodiment, the GEP inhibitor is an antibody, aptamer, or binding partner that binds specifically to human GEP.

[0077] In one embodiment, the cDNA sequence of a GEP useful according to the present invention is SEQ ID NO. 1. In one embodiment, the GEP protein useful according to the present invention comprises an amino acid sequence of SEQ ID NO. 2.

[0078] In a further specific embodiment, the GEP inhibitor is an antibody, aptamer, or binding partner that binds specifically to GEP of SEQ ID NO. 2.

[0079] Embodiments of anti-GEP antibodies are also described in WO2008/064570, which is herein incorporated by reference in its entirety.

[0080] In one specific embodiment, the present invention provides a method for treating liver cancer, wherein the method comprises administering, to a subject that has liver cancer, a composition comprising an antibody that binds to granulin-epithelin precursor (GEP), and, optionally, NK cells and/or an agent that promotes natural killer (NK) cell activity.

[0081] In certain embodiments, the GEP inhibitor is an antibody, aptamer, or binding partner that binds specifically to a GEP protein of non-human animal species including, but not limited to, dogs, cats, horses, pigs, sheep, goats, chickens, mice, rats, and guinea pigs. The skilled artisan can readily make antibodies, aptamers, or binding partners that specifically bind to GEP proteins that are publically known. In another embodiment, the GEP inhibitor is a fusion construct comprising the antibody, aptamer, or binding partner that binds specifically to a GEP protein (such as human GEP).

[0082] In one embodiment, GEP-specific antibodies can be generated by immunizing BALB/c mice or New Zealand white rabbits with GEP specific peptide sequences, as described in WO2008/064570, which is herein incorporated by reference in its entirety.

[0083] “Specific binding” or “specificity” refers to the ability of a protein to detectably bind an epitope presented on a protein or polypeptide molecule of interest, while having relatively little detectable reactivity with other proteins or structures. Specificity can be relatively determined by binding or competitive binding assays, using, e.g., Biaxcel instruments. Specificity can be exhibited by, e.g., an about 10:1, about 20:1, about 50:1, about 100:1, 10,000:1 or greater ratio of affinity/avidity in binding to the specific target molecule versus nonspecific binding to other irrelevant molecules.

[0084] Anti-GEP antibodies of the present invention can be in any of a variety of forms, including intact immunoglobulin molecules, fragments of immunoglobulin molecules such as Fv, Fab and similar fragments; multimers of immunoglobulin molecules (e.g., diabodies, triabodies, and bi-specific and tri-specific antibodies, as are known in the art; see, e.g., Hudson and Kortt, J. Immunol. Methods 231:177 189, 1999); fusion constructs containing an antibody or antibody fragment; and human or humanized immunoglobulin molecules or fragments thereof.

[0085] Antibodies within the scope of the invention can be of any isotype, including IgG, IgA, IgE, IgD, and IgM. IgG isotype antibodies can be further subdivided into IgG1, IgG2, IgG3, and IgG4 subtypes. IgA antibodies can be further subdivided into IgA1 and IgA2 subtypes.

[0086] Antibodies of the present invention include polyclonal and monoclonal antibodies. The term “monoclonal antibody,” as used herein, refers to an antibody or antibody fragment obtained from a substantially homogeneous population of antibodies or antibody fragments (i.e. the individual antibodies within the population are identical except for possible naturally occurring mutations that may be present in a small subset of the antibody molecules).

[0087] A monoclonal antibody composition is typically composed of antibodies produced by clones of a single cell called a hybridoma that secretes (produces) only one type of antibody molecule. The hybridoma cell is formed by fusing an antibody-producing cell and a myeloma or other self-perpetuating cell line. Such antibodies were first described by Kohler and Milstein, Nature, 1975, 256:495-497, the disclosure of which is herein incorporated by reference. An exemplary hybridoma technology is described by Nimmer et al., Proc. Natl. Acad. Sci. U.S.A., 1983, 80:4949-4953. Other methods of producing monoclonal antibodies, a hybridoma cell, or a hybridoma cell culture are also well known. See, e.g., Antibodies: A Laboratory Manual, Harlow et al., Cold Spring Harbor Laboratory, 1988; or the method of isolating monoclonal antibodies from an immunological repertoire as described by Sasastry et al., Proc. Natl. Acad. Sci. USA, 1989,

[0088] In an embodiment, the GEP inhibitor is a GEP antisense polynucleotide. In an embodiment, the GEP inhibitor is an antisense polynucleotide that targets human GEP mRNA. In some embodiments, the GEP antisense polynucleotides target GEP mRNAs of non-human animals including, but not limited to, dogs, cats, horses, pigs, sheep, goats, chickens, mice, rats, and guinea pigs. The skilled artisan would readily appreciate that the antisense polynucleotides can be designed to target any GEP mRNAs publically known.

[0089] In some embodiments, the GEP inhibitor is a siRNA or shRNA having a sequence sufficiently complementary to a target GEP mRNA sequence to direct target-specific RNA interference (RNAi). In some embodiments, the GEP inhibitor is siRNA or shRNA having a sequence sufficiently complementary to a target human GEP mRNA sequence to direct target-specific RNA interference.

[0090] Examples of antisense polynucleotides include, but are not limited to, single-stranded DNAs and RNAs that bind to complementary target GEP mRNA and inhibit translation and/or induce RNaseI-mediated degradation of the target transcript; siRNA or shRNA oligonucleotides that target or mediate GEP mRNA degradation; ribozymes that cleave GEP mRNA transcripts; and nucleic acid aptamers and decoys, which are non-naturally occurring oligonucleotides that bind to and block GEP protein targets in a manner analogous to small molecule drugs.

[0091] The term “nucleotide” refers to a nucleoside having one or more phosphate groups joined in ester linkages to the sugar moiety. Exemplary nucleotides include nucleoside monophosphates, diphosphates and triphosphates. The terms “polynucleotide” and “nucleic acid molecule” are used interchangeably herein and refer to a polymer of nucleotides joined together by a phosphodiester linkage between 5’ and 3’ carbon atoms. The terms “nucleic acid” or “nucleic acid sequence” encompass an oligonucleotide, nucleotide, polynucleotide, or a fragment of any of these, DNA or RNA of genomic or synthetic origin, which may be single-stranded or double-stranded and may represent a sense or antisense strand, peptide nucleic acid (PNA), or any DNA-like or RNA-like material, natural or synthetic in origin. As will be understood by those of skill in the art, when the nucleic acid is RNA, the deoxynucleotides A, G, C, and U, respectively.

[0092] As used herein, the term “RNA” or “RNA molecule” or “ribonucleic acid molecule” refers generally to a polymer of ribonucleotides. The term “DNA” or “DNA molecule” or “deoxyribonucleic acid molecule” refers generally to a polymer of deoxyribonucleotides. DNA and RNA molecules can be synthesized naturally (e.g., by DNA replication or transcription of DNA, respectively). RNA molecules can be post-translationally modified. DNA and RNA molecules can also be chemically synthesized. DNA and RNA molecules can be single-stranded (i.e., siRNA and dsDNA, respectively) or double-stranded (e.g., dsDNA and dsRNA, respectively). Based on the nature of the invention, however, the term “RNA” or “RNA molecule” or “ribonucleic acid molecule” can also refer to a polymer comprising primarily (i.e., greater than 80% or, preferably greater than 90%) ribonucleotides but optionally including at least one non-ribonucleotide molecule, for example, at least one deoxyribonucleotide and/or at least one nucleotide analog.

[0093] As used herein, the term “nucleotide analog,” also referred to herein as an “altered nucleotide” or “modified nucleotide,” refers to a non-standard nucleotide, including non-naturally occurring ribonucleotides or deoxyribonucleotides. Preferred nucleotide analogs are modified at any position so as to alter certain chemical properties of the nucleotide yet retain the ability of the nucleotide analog to perform its intended function.

[0094] As used herein, the term “RNA interference” (“RNAi”) refers to a selective intracellular degradation of RNA. RNAi occurs in cells naturally to remove foreign RNAs (e.g., viral RNAs). Natural RNAi proceeds via fragments cleaved from free dsRNA which direct the degradative mechanism to other similar RNA sequences. Alternatively, RNAi can be initiated by the hand of man, for example, to silence the expression of endogenous target genes.

[0095] As used herein, the term “small interfering RNA” (“siRNA”) (also referred to in the art as “short interfering RNAs”) refers to an RNA (or RNA analog) comprising between about 10-50 nucleotides (or nucleotide analogs) which is capable of directing or mediating RNA interference.

[0096] As used herein, a siRNA having a sequence sufficiently complementary to a target mRNA sequence to direct target-specific RNA interference (RNAi) means that the siRNA has a sequence sufficient to trigger the destruction of the target mRNA (e.g., GEP mRNA) by the RNAi machinery or process. “mRNA” or “messenger RNA” or “transcript” is single-stranded RNA that specifies the amino acid sequence of one or more polypeptides. This information is translated during protein synthesis when ribosomes bind to the mRNA.

[0097] The present invention also contemplates vectors (e.g., viral vectors) and expression constructs comprising the nucleic acid molecules useful for inhibiting GEP expression and/or activity. In an embodiment, the vector comprises a siRNA that targets GEP mRNA. In another embodiment, the vector comprises a nucleic acid molecule encoding an anti-GEP A antibody.

[0098] As used herein, the term “expression construct” refers to a combination of nucleic acid sequences that provides for transcription of an operably linked nucleic acid sequence. As used herein, the term “operably linked” refers to a juxtaposition of the components described, wherein the components are in a relationship that permits them to function in their intended manner. In general, operably linked components are in contiguous relation.

[0099] Expression constructs of the invention will also generally include regulatory elements that are functional in the intended host cell in which the expression construct is to be expressed. Thus, a person of ordinary skill in the art can select regulatory elements for use in, for example, bacterial host cells, yeast host cells, mammalian host cells, and human host cells. Regulatory elements include promoters, transcription termination sequences, translation termination sequences, enhancers, and polyadenylation elements.

[0100] An expression construct of the invention can comprise a promoter sequence operably linked to a polynucleotide sequence encoding a peptide of the invention. Promoters can be incorporated into a polynucleotide using standard techniques known in the art. Multiple copies of promoters or multiple promoters can be used in an expression construct of the invention. In a preferred embodiment, a promoter can be positioned about the same distance from the transcription start site as it is from the transcription start site in its natural genetic environment. Some variation in this distance is per-
mitted without substantial decrease in promoter activity. A transcription start site is typically included in the expression construct.

[0010] Agents that Promote NK Cell Activity

[0011] In certain embodiments, agents that promote NK cell activity include, but are not limited to, agents that promote expansion and maturation of NK cells, and agents that enhance cytotoxicity of NK cells. Various agents that enhance NK cell activity are known in the art. In certain embodiments, agents that enhance NK cell activity include, but are not limited to, IL-15, IL-12, pectin, interferons (such as IFN-gamma), II-2, and II-1.

[0012] Interleukin-12 (II-12) is a cytokine that promotes and stimulates activity of NK cells and T lymphocytes, and has antitumor activity (U.S. Patent Application Publication No. 2012/0251441).


[0016] Interferons (such as, IFN-gamma) and II-2 have been shown to promote NK cell activity.

Therapeutic Compositions and Routes of Administration

[0017] The subject invention further provides for therapeutic or pharmaceutical compositions.

[0018] In an embodiment, the composition comprises a therapeutically effective amount of a protein, nucleic acid molecule, and/or compound of the subject invention and, optionally, a pharmaceutically acceptable carrier.

[0019] The subject invention contemplates therapeutic compositions useful for practicing the therapeutic methods described herein. The therapeutic composition can be any form of pharmaceutical format, including injectable formulations such as liquid and lyophilized injections.

[0020] Suitable non-toxic pharmaceutically acceptable carriers for use with the agent will be apparent to those skilled in the art of pharmaceutical formulation. See, for example, Remington’s *Pharmaceutical Sciences*, seventeenth edition, ed. Alfonso R. Gennaro, Mack Publishing Company, Easton, Pa. (1985). Suitable carriers include ethanol, dimethyl sulfoxide, glycerol, silica, alumina, starch, sorbitol, inositol, xylitol, D-xylene, mannitol, powdered cellulose, microcrystalline cellulose, talc, colloidal silicon dioxide, calcium carbonate, magnesium carbonate, calcium phosphate, calcium aluminium silicate, aluminium hydroxide, sodium starch phosphate, lecithin, and equivalent carriers and diluents. Saline solutions and aqueous dextrose and glycerol solutions can also be employed as liquid carriers, particularly for injectable solutions.

[0021] Suitable pharmaceutical excipients include starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, gelatin, propylene, glycol, water, ethanol, and the like. The therapeutic composition, if desired, can also contain minor amounts of wetting or emulsifying agents, or pH buffering agents.

[0022] The amount of active ingredient that may be combined with the carrier materials to produce a single dosage form will vary, depending on the type of the condition and the subject to be treated. In general, a therapeutic composition contains from about 5% to about 95% active ingredient (w/w). More specifically, a therapeutic composition contains from about 20% (w/w) to about 80%, or about 30% to about 70%, active ingredient (w/w).

[0023] The preparation of a pharmacological composition that contains active ingredients dissolved or dispersed therein is well understood in the art and need not be limited based on formulation. Typically such compositions are prepared as injectables either as liquid solutions or suspensions; however, solid forms suitable for solution, or suspensions, in liquid prior to use also can be prepared. The preparation also can be emulsified.

[0024] The therapeutic composition of the subject invention can include pharmaceutically acceptable salts of the components therein. Pharmaceutically acceptable salts include the acid addition salts (formed with the free amino groups of a polypeptide) that are formed with inorganic acids such as, for example, hydrochloric or phosphoric acids, or such organic acids as acetic, tartaric, mandelic and the like. Salts formed with the free carboxyl groups also can be derived from inorganic bases such as, for example, sodium, potassium, ammonium, calcium or ferric hydroxides, and such organic bases as isopropylamine, trimethylamine, 2-ethylamino ethanol, histidine, procaine and the like.

[0025] As used herein, the terms “pharmaceutically acceptable”, “physiologically tolerable” and grammatical variations thereof, as they refer to compositions, carriers, diluents and reagents, are used interchangeably and represent that the materials are capable of administration to or upon a mammal.

[0026] The invention also provides a pharmaceutical pack or kit comprising one or more containers filled with one or more of the ingredients, e.g., compound, carrier suitable for administration.

[0027] The compositions of the subject invention can be administered to the subject being treated by standard routes, including oral, inhalation, or parenteral administration including intravenous, subcutaneous, topical, transdermal, intradermal, transmucosal, intraperitoneal, intramuscular, intracapsular, intraorbital, intracarotid, intratracheal, subcutaneous, subcuticular, intraarticular, subcapsular, subarachnoid, intraspinal, epidural and intrasternal injection, infusion,
Tumor and adjacent non-tumor tissue pair from HCC patients were collected and examined for the expression of GEP, MICA and HLA-E by real-time quantitative reverse-transcription polymerase chain reaction (RT-PCR), immunohistochemistry and flow cytometry. Sera of HCC patients and healthy donors were collected for measurement of soluble MICA (sMICA) and GEP levels.

**Immunofluorescence Staining and Flow Cytometric Analysis**

For HCC cell surface expression of ligands for NK cell immunoreceptors, cells were stained with APC-conjugated mouse anti-human MICA, HLA-A/B/C, HLA-G, PE-conjugated mouse anti-human HLA-E antibodies or equal amount of corresponding isotype control (BD Biosciences). For co-expression with GEP, cells were stained with the above surface markers, followed by permeabilization with ice-cold 0.1% saponin and then incubated with FITC-conjugated mouse anti-human GEP antibody (described previously) or equal amount of FITC-conjugated mouse IgG isotype antibody (Sigma). For NKGD2 surface expression on NK cells, cells were stained with APC-conjugated mouse anti-NKGD2 antibody or equal amount of corresponding isotype control (BD Biosciences). Results were expressed as percentage of cells positive for the above markers and/or mean fluorescence intensity (MFI) of the markers, after subtracting the non-specific background signal (isotype controls).

**Preparation of Human Effector Cells**

Human peripheral blood mononuclear cells (PBMC) were freshly isolated from the buffy coats of healthy donors by density gradient centrifugation using Ficoll-Paque Plus. NK cells were isolated from PBMC using magnetic cell sorting by positive selection with anti-CD56 microbeads, while the unlabeled flow-through were the NK cell-depleted PBMCs, according to the manufacturer’s instructions (Miltenyi Biotech). The resulting PBMCs, NK cells, and NK cell-depleted PBMCs were washed with RPMI 1640 with 10% FBS and used as human effector cells in the cell cytotoxicity assay.

**Cell Cytotoxicity Assay**

Cell cytotoxicity was determined by dual-color flow cytometry using the HCC cell lines Hep3B or HepG2 as target cells, while PBMC, NK cells, or NK cell-depleted PBMCs were used as effector cells. Briefly, HCC cells (1×10⁶ cells/ml) were labeled with the green fluorescence cytoplasmic dye 5- and 6-carboxyfluorescein diacetate, succinimidyl ester (CFSE) at 0.1 μM for 15 min at 37°C in dark. After washing, CFSE-labeled HCC cells were then co-cultured with or without effector cells at indicated effector to target cells ratio (E/T ratio) in RPMI supplemented with 10% FBS for additional 5 hr at 37°C. In 5% CO2. Cells were then collected and stained with 10 μg/ml propidium iodide (PI) for 15 min at room temperature in dark. Cells were subject to dual-color flow cytometric analysis, with lysed target cells recognized as CFSE⁺PI⁺, while viable target cells as CFSE⁻PI⁻. Cell cytotoxicity level was expressed as percentage of lysed cells within the CFSE⁺ target cells (Hep3B or HepG2), and calculated as follows:

**Percentage of CFSE⁺PI⁺ cells**

(Percentage of CFSE⁺PI⁺ cells × 100)

**Materials and Methods**

**Cell Culture and Assays**

Human HCC cell lines, Hep3B and HepG2, were purchased from American Type Culture Collection (Manassas, Va.) and were cultured; while HuH7 was purchased from Health Science Research Resources Bank (Osaka, Japan) and maintained in Dulbecco’s modified Eagle medium (DMEM) supplemented with 10% heat-inactivated fetal bovine serum (Invitrogen, Carlsbad, Calif.).

Stable transfectant for GEP over-expression was established by transfecting GEP full-length cDNA into HepG2, a cell line with low endogenous GEP level; while GEP suppression was performed by transfecting GEP shRNA into Hep3B, a cell line with high endogenous GEP level. Both GEP over-expression and suppression transfectants were maintained in 10% AMEM with 0.4 mg/ml G418.

GEP blockade in Hep3B was performed by incubating the cells with or without 50 μg/ml anti-GEP monoclonal antibody A23 or mouse IgG isotype control antibody (Sigma-Aldrich, St. Louis, Mo.) for 24 hr. GEP stimulation in HepG2 cells was performed by incubating the cells with or without 0.8 μg/ml recombinant GEP for 24 hr.

**Clinical Specimens**

The study protocol was approved by the Institutional Review Board of the University of Hong Kong/Hospital Authority Hong Kong West Cluster (HKU/HA HKW IRB). Five patients who underwent curative partial hepatectomy or liver transplantation for HCC at Queen Mary Hospital, Hong Kong, were recruited with written informed consent to the study. The patients had been diagnosed with primary HCC and confirmed by pathological examinations. Ethics approval for the use of archival fetal tissues identified from a computer database has been obtained from the Institutional Review Board of the University of Hong Kong/Hospital Authority Hong Kong West Cluster (HKU/HA HKW IRB).
For blocking experiments, neutralization of MICA was performed by incubating the CFSE-labeled HCC cells with or without anti-MICA neutralizing antibody or mouse IgG2a isotype control antibodies (2 μg/ml, Biologend) and co-cultured with effector cells.

For antibody-dependent cytotoxicity (ADCC), CFSE-labeled HCC cells were stained with or without indicated concentrations of anti-GEP antibody A23, or mouse IgG1 isotype antibody for 30 min at 4°C. Labeled target cells were then co-cultured with effector cells at indicated E/T ratio.

Orthotopic Mouse Model

The establishment of an orthotopic mouse model and drug treatments was described (Wong N C et al., Mol Cancer Therapeutics, 2014-0012 in revision). Briefly, Hep3B cells transfected with firefly luciferase activity were injected subcutaneously into the right flank of 4-5 weeks old male BALB/c nude mice and were observed daily for signs of tumor development. Once the subcutaneous tumor reached 1-1.5 cm in diameter, it was removed, cut into 1-2 mm cubes and implanted into the left lobe of another group of 4-5 weeks old nude mice under anesthesia. The size of tumor was monitored by the in vivo imaging system, IVIS100 (Caliper Life Sciences, Hopkinton, Mass., USA) with intra-peritoneal (i.p.) injection of 150 mg/kg of D-Luciferin (Gold Biotechnology, St Louis, Mo., USA) under anesthesia. The tumor take rate was confirmed and experiments were started with ROI greater than 1×10^4 p/s/cm²/sr. The bioluminescent signal intensity emitted from the intrahepatic tumor was quantified weekly with Living Image Software (Caliper Life Sciences). Mice bearing intrahepatic Hep3B tumors were randomized and received i.p. injection of saline (control) (n=3) or 10 mg/kg anti-GEP antibody twice weekly (n=3). Mice were sacrificed after six weeks of treatment. Tumors were dissected and embedded with paraffin for further analysis.

Enzyme-linked Immunosorbent Assay (ELISA) to Determine GEP and MICA Levels

Soluble MICA levels in culture supernatants and human serum samples were determined by DuoSet MICA ELISA kit (R&D Systems, Minneapolis, Minn.). GEP levels in human serum samples were determined by human progranulin ELISA kit (Adipogen Inc., Seoul, Korea).

Immunohistochemical Staining

Immunohistochemistry was performed with the Dako Envision Plus System (Dako, Carpinteria, Calif.) following the manufacturer’s instruction with modifications. Briefly, antigen retrieval was performed by microwave with sections immersed in citrate buffer. Followed by endogenous peroxidase blocking, tissues were stained with mouse anti-human GEP antibody (described previously), goat anti-human MICA (R&D Systems) and mouse anti-human HLA-E (Abcam, Cambridge, Mass.). The signal was detected by horseradish peroxidase-conjugated secondary antibody and color was developed with diaminobenzidine as the chromagen. The tissue sections were then counterstained with hematoxylin.

Real-Time Quantitative Reverse-Transcription Polymerase Chain Reaction

Real-time quantitative RT-PCR was performed as described previously (Cheung S T et al., Clin Cancer Res. 2004). Quantification was performed with the ABI Prism 7700 sequence detection system (Applied Biosystems, Foster City, Calif.). Primers and probe for GEP have previously been described. Primers and probe were ready-made reagents (Pre-Developed TaqMan Assay Reagents; Applied Biosystems) for MICA (catalog no./assay ID: Hs00792195_m1), HLA-E (catalog no./assay ID: Hs01045171_m1), and control 18 s. In brief, there were 40 amplification cycles. The sample would be regarded as absent GEP, MICA or HLA-E expression when there was no detectable signal of GEP, MICA or HLA-E up to 40 cycles. The relative amount of GEP, MICA and HLA-E, which had been normalized with control 18 s for RNA amount variation and calibrator for plate-to-plate variation, was presented as the relative fold change.

Statistical Analyses

All analyses were performed using the statistical software GraphPad Prism Version 3.00 for Windows (GraphPad Software, CA, USA) or SPSS version 16.0 for Windows (SPSS Inc, Chicago, Ill.). All in vitro data were expressed as mean values±standard deviation (SD) from at least three independent experiments. Continuous variables were assessed by Spearman correlation and compared between groups by ANOVA (clinical samples) or Student t test (in vitro models). GEP, MICA and HLA-E transcript levels were continuous variables, and the data were modeled as categorical variables in Kaplan-Meier and Cox regression analyses. The Youden index (i.e., sensitivity+specificity-1) was used to determine the optimal cutoff point for the prediction of 3-year recurrence-free survival maximizing the sensitivity and the specificity of the prediction. The association of GEP, MICA, and tumor stage (American Joint Committee on Cancer tumor staging system version 7) with recurrence-free survival was examined by univariable and multivariable Cox proportional hazards regression with a forward stepwise selection procedure. P value <0.05 was considered statistical significant.

EXAMPLES

Following are examples that illustrate procedures for practicing the invention. These examples should not be construed as limiting.

Example 1

GEP Expression of HCC Cells Modulates Anti-Tumor Cytotoxic Activity of Immune Cells

It is postulated that only a restricted minority of tumorigenic malignant cells may possess the characteristics needed to modulate tumor-directed immune activation. To examine the effect of GEP on anti-tumor immunity, a stable transfectant of GEP expression was established using shRNA in Hep3B, a HCC cell line with high endogenous GEP; a stable transfectant of GEP over-expression was established using GEP full-length cDNA in HepG2, a HCC cell line with low endogenous GEP level. Results from qPCR and flow cytometry showed that GEP mRNA and protein levels were significantly down-regulated in Hep3B cells, and up-regulated in HepG2 cells (Fig. 1A).
Cytotoxic activity of human PBMC against the HCC cells and their GEP transfectants was examined by dual-color flow cytometry. Cytotoxic activity of human PBMC against GEP-suppressed Hep3B cells was significantly higher than control Hep3B cells. On the contrary, cytotoxic activity of PBMC against HepG2 cells was significantly reduced when GEP was over-expressed.

The results show that GEP expression is crucial for rendering HCC cells resistant to anti-tumor cytotoxic activity of PBMC (FIG. 1B).

PBMC encompasses a variety of immune cells including T and B lymphocytes, monocytes, natural killer (NK) cells, and dendritic cells. The anti-tumor activity of NK cells in liver has been well documented. Clinical studies also suggest that NK cells contribute to innate defenses against primary liver tumors and liver metastases in patients.

To evaluate whether NK cells are involved in the GEP-modulated immunomodulation, CD56+ NK cells were depleted from human PBMC by magnetic sorting. Upon NK cell depletion, the increased cytotoxic activity against GEP-suppressed Hep3B cells was abolished; while the reduction of cytotoxic activity against GEP over-expressed HepG2 was restored (FIG. 1C).

To further confirm the role of NK cells, HCC cells and their GEP transfectants were co-cultured with NK cells at different E:T ratio. Cytotoxic activity of NK cells against GEP-suppressed Hep3B cells was significantly higher than that against control Hep3B cells; while significant reduction in NK cytotoxic activity was demonstrated in GEP over-expressed HepG2 cells when compared with control HepG2 cells. Besides, cytotoxicity against HCC cells increased as the number of NK cells increased (FIG. 1D). The results show that the GEP-regulated anti-tumor cytotoxicity was dependent on NK cells.

Since the NK cells of the previously described studies herein were isolated from lymphocytes of healthy individuals, it was necessary to determine if the same effect is observed when the NK cells are isolated from liver cancer patients. NK cells isolated from liver cancer patients showed enhanced cytotoxicity in liver cancer cells with GEP suppression (Hep3B cells transfectected with GEP shRNA, 3B-sh1) (FIG. 1E) and showed decreased cytotoxicity in liver cancer cells with GEP over-expression (HepG2 transfected with GEP full-length, G2FL) (FIG. 1F). As such, activation of NK cells in liver cancer patients, by GEP antibody or other inhibitors, could result in control of tumor growth without transfusion of NK cells from healthy counterparts.

Example 3

GEP Blockage by Anti-GEP Antibody A23 Modulates the Expression of MICA and HLA-E of HCC Cells

To further validate the regulatory role of GEP on the expression of MICA and HLA-E, GEP blockage by anti-GEP monoclonal antibody A23 was performed in Hep3B cells. A23, but not mouse IgG, significantly suppressed GEP expression of Hep3B cells (FIG. 3A), demonstrating the suppressing effect was specific. A23 was found to significantly increase the expression of surface MICA, while decrease soluble MICA release and surface HLA-E expression of Hep3B when compared with control and isotype control treatment (FIG. 3B).

To confirm the regulatory role of anti-GEP antibody A23 in vivo, orthotopic tumors were generated of Hep3B cells in nude mice. Tumor bearing mice were subject to saline (control) or 10 mg/kg anti-GEP antibody twice weekly for six weeks. No signs of disability and behavior abnormalities were observed during the treatment period. GEP antibody treatment was found to significantly suppress tumor growth when compared with saline control in terms of tumor volumes and tumor sizes (Wong, N C et al. submitted manuscript). Protein expression of GEP, MICA and HLA-E in the tumors was detected by immunohistochemical staining A23 was found to markedly reduce the protein expression of GEP, but increase that of MICA significantly when compared with saline control (FIG. 3B). However, HLA-E protein could not be detected in the xenograft tumors (data not shown), which was probably due to the low constitutive expression level of
HLA-E protein in Hep3B cells. The results indicated that A23 could reduce tumor growth in vivo, which might be at least partially due to the suppression of GEP and up-regulation of MICA levels of HCC cells, thereby facilitating NK cytotoxicity against the tumors.

Example 4

GEP Blockage by Anti-GEP Antibody A23 Enhances NK Cell Cytotoxicity Against HCC Cells Via MICA

[0149] Confirming the role of GEP in tumor immune evasion, the therapeutic potential of anti-GEP monoclonal antibody A23 in anti-tumor immunity in HCC was studied. HCC cells were treated with A23 or isotype control antibody for 24 h prior to co-culture with PBMC to assess the effect of A23 on anti-tumor cytotoxic activity against HCC cells. Results showed that cytotoxic activities of PBMC against A23-treated Hep3B and HepG2 cells were significantly higher than those of control and isotype control antibody-treated cells (Fig. 4A). Note that the increase in HepG2 cells that were sensitized to PBMC cytotoxicity upon A23 treatment was smaller than those observed in Hep3B. This is probably because HepG2 cells constitutively express lower level of endogenous GEP than Hep3B cells, the magnitude of GEP reduction by A23 in HepG2 is smaller than that in Hep3B, resulting in the smaller magnitude of A23-induced effect observed in HepG2.

[0150] To examine the role of MICA in A23-induced PBMC cytotoxicity against HCC cells, blocking antibody of MICA was used. HCC cells were treated with A23 for 24 h and then incubated with anti-MICA neutralizing antibody or isotype control (mouse IgG2a) and co-cultured with PBMC. Addition of anti-MICA blocking antibody, but not mouse IgG2a isotype control, could markedly abrogate the A23-induced cytotoxicity against Hep3B and HepG2 cells. The results suggested that the A23-induced cytotoxic activity against HCC cells was dependent on MICA. (Fig. 4A)

[0151] Since the MICA-NKG2D signal is important for NK cell activation, the effect of MICA neutralization on A23-induced NK sensitivity of HCC cells was studied. Results showed that blocking MICA could significantly abolish the A23-induced NK sensitivity of HCC cells at different E:T ratios, therefore confirming that A23-induced NK cytotoxicity against HCC cells was dependent on MICA (Fig. 4B).

Example 5

Antibody-Dependent Cellular Cytotoxicity Mediated by Anti-GEP Monoclonal Antibody A23

[0152] To further characterize the immunomodulatory mechanism of anti-GEP monoclonal antibody A23, antibody-dependent cellular cytotoxicity (ADCC) of A23 was assessed. ADCC occurs when antibodies bind to antigen on tumor cells and the antibody Fc domains engage Fc receptors on the surface of immune effector cells. Hep3B or HepG2 cells were stained with or without anti-GEP antibody A23 or mouse isotype control antibody for 30 min and the antibody-labeled cancer cells were then co-cultured with PBMC. A23, but not isotype control antibody, significantly induced ADCC of human PBMC against both Hep3B and HepG2 cells in a dose-dependent manner (Fig. 6A). The results show that the anti-tumor activity of A23 was at least partly attributable to ADCC.

[0153] In addition, this Example further elucidates which effector cells are important for the ADCC activity of A23 in human. NK cells were depleted from PBMC and the A23-mediated ADCC in both cell lines was markedly abolished upon depletion of NK cells from PBMC (Fig. 6B). A23-labeled cancer cells were then co-cultured with NK cells and the A23-mediated ADCC against the HCC cells increased along the E:T ratio (Fig. 6C). Therefore, it was confirmed that NK cells also play an important role as effector cells for the A23-induced ADCC in human.

Example 6

Expression Patterns of GEP, MICA and HLA-E in HCC Clinical Specimens

[0154] GEP and MICA transcript levels were found to be significantly elevated in HCC when compared with paralleled tumor adjacent non-tumor liver tissues and normal livers from healthy individuals (both p<0.001). HLA-E transcript level was also elevated in HCC when compared with non-tumor liver tissues and normal livers, though statistical significance was not reached (p=0.089) (Fig. 5A). By immunohistochemical staining, it was revealed that total protein expression levels of GEP, MICA and HLA-E were stronger in HCC when compared with their adjacent non-tumor liver tissues (Fig. 5B). Besides, serum GEP and MICA levels were found to significantly higher in HCC patients when compared with healthy individuals (p<0.010 and p<0.001, respectively) (Fig. 5C).

[0155] It is shown that GEP conferred HCC cells resistance to NK cytotoxicity by differentially regulated surface MICA and HLA-E expression in HCC cell lines. To confirm the immunoevasion ability of GEP-expressing cells in clinical settings, cell surface MICA and HLA-E were co-stained with GEP in HCC clinical specimens by immunofluorescence staining and flow cytometry. Results showed that expressions of surface MICA and GEP were mutually exclusive (n=3) (Fig. 5D). However, surface HLA-E were found to co-express with GEP in the HCC clinical specimens (n=3) (Fig. 5D). The result therefore echoes that of cell line model that GEP down-regulated MICA, but up-regulated HLA-E on the surface of HCC cells, rendering the cells less susceptible to NK cytotoxicity. Note that in primary HCC fresh tissues, GEP+ cells only contributed to less than 5% of the whole tumor bulk, which was comparable to the other hepatic CSC markers such as CD133 (Ma S et al. Cell stem cell. 2010) and CD90 (Yang Z F, et al. Cancer Cell. 2008). Such small proportion was actually in accordance with the definition of CSCs, that only a minority of cells in the tumor bulk was able to self-renew and regenerate the tumors (Reya, T et al. Nature. 2001).

Example 7

Association of Serum GEP and MICA Levels with Clinico-Pathological Parameters

[0156] To investigate the potential of GEP and MICA as predictive or prognosis markers for HCC, the association of serum GEP and MICA levels with clinico-pathological parameters in HCC patients (n=80) was determined. Here, it was found that serum GEP levels significantly correlated with tumor size (HCC n=80, Spearman’s p correlation coefficient=-0.569, p<0.001) (Table 1). Previous study has suggested serum MICA level as a potential prognostic marker for
HBV-induced HCC (Kumar, V et al. *PLoS One*. 2012). However, no significant association was found between serum MICA level and HBV infection in the patient cohort. Kaplan-Meier plot was used to examine patient outcome in association with serum GEP and MICA levels. Patients were segregated into low expression group (low in both serum GEP and MICA) and high expression group (either one or both high in serum GEP and MICA) with the Youden index maximized to determine optimal cutoff value. There were 25 patients in the low expression group (median recurrence-free survival, 51.2 months) and 55 patients in the high expression group (median recurrence-free survival, 12.8 months). Patients with high serum GEP and/or MICA levels were found to have poor recurrence-free survival (log-rank test, p<0.042) (FIG. 7A). When the patients were segregated into early (FIG. 7B) and advanced (FIG. 7C) tumor stages, patients with high serum GEP and/or MICA levels were also found to have poor recurrence-free survival.

**TABLE 1**

Clinicopathological features of HCC in relation to sGEP and sMICA levels.

<table>
<thead>
<tr>
<th>Clinicopathological variables</th>
<th>sGEP low</th>
<th>sGEP high</th>
<th>P value</th>
<th>MICA low</th>
<th>MICA high</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Venous infiltration</td>
<td>23</td>
<td>16</td>
<td>0.179</td>
<td>20</td>
<td>19</td>
<td>1.000</td>
</tr>
<tr>
<td>Tumor size</td>
<td>17</td>
<td>24</td>
<td>0.21</td>
<td>20</td>
<td>20</td>
<td>1.000</td>
</tr>
<tr>
<td>Small (&lt;5 cm)</td>
<td>18</td>
<td>5</td>
<td>0.003**</td>
<td>10</td>
<td>13</td>
<td>0.622</td>
</tr>
<tr>
<td>Large (&gt;5 cm)</td>
<td>22</td>
<td>35</td>
<td>0.30</td>
<td>30</td>
<td>27</td>
<td>1.000</td>
</tr>
<tr>
<td>Tumor capsule</td>
<td>11</td>
<td>11</td>
<td>0.712</td>
<td>10</td>
<td>12</td>
<td>0.067</td>
</tr>
<tr>
<td>pTNM stage</td>
<td>4</td>
<td>7</td>
<td>0.09</td>
<td>9</td>
<td>2</td>
<td>1.000</td>
</tr>
<tr>
<td>Early stage (I-II)</td>
<td>26</td>
<td>25</td>
<td>1.000</td>
<td>27</td>
<td>24</td>
<td>0.642</td>
</tr>
<tr>
<td>Late stage (III-IV)</td>
<td>14</td>
<td>15</td>
<td>13</td>
<td>16</td>
<td>13</td>
<td>1.000</td>
</tr>
<tr>
<td>Gender</td>
<td>30</td>
<td>30</td>
<td>1.000</td>
<td>30</td>
<td>30</td>
<td>1.000</td>
</tr>
<tr>
<td>Age</td>
<td>10</td>
<td>10</td>
<td>10</td>
<td>10</td>
<td>10</td>
<td>1.000</td>
</tr>
<tr>
<td>Young (≤60)</td>
<td>27</td>
<td>26</td>
<td>1.000</td>
<td>27</td>
<td>26</td>
<td>1.000</td>
</tr>
<tr>
<td>Elderly (&gt;60)</td>
<td>13</td>
<td>14</td>
<td>13</td>
<td>14</td>
<td>13</td>
<td>1.000</td>
</tr>
<tr>
<td>Serum AFP level</td>
<td>14</td>
<td>16</td>
<td>0.818</td>
<td>13</td>
<td>17</td>
<td>0.489</td>
</tr>
<tr>
<td>Low (≤20 ng/ml)</td>
<td>24</td>
<td>26</td>
<td>27</td>
<td>23</td>
<td>27</td>
<td>1.000</td>
</tr>
<tr>
<td>High (&gt;20 ng/ml)</td>
<td>16</td>
<td>16</td>
<td>0.30</td>
<td>16</td>
<td>16</td>
<td>1.000</td>
</tr>
<tr>
<td>HBV association</td>
<td>24</td>
<td>24</td>
<td>1.000</td>
<td>24</td>
<td>24</td>
<td>1.000</td>
</tr>
</tbody>
</table>

**TABLE 2**

Cox regression analyses for recurrence-free survival on sGEP/MICA levels and tumor stage.

<table>
<thead>
<tr>
<th>Variables</th>
<th>n</th>
<th>HR (95% CI)</th>
<th>P value</th>
<th>adjusted HR (95% CI)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>sGEP</td>
<td>Low</td>
<td>25</td>
<td>1</td>
<td>1.000</td>
<td>1.000</td>
</tr>
<tr>
<td>sMICA</td>
<td>High</td>
<td>55</td>
<td>1.9</td>
<td>0.045</td>
<td>1.05 (1.0-3.5)</td>
</tr>
<tr>
<td>Tumor stage</td>
<td>Early</td>
<td>51</td>
<td>1</td>
<td>1.000</td>
<td>1.000</td>
</tr>
<tr>
<td></td>
<td>Late</td>
<td>29</td>
<td>2.3</td>
<td>0.001</td>
<td>1.05 (1.0-3.5)</td>
</tr>
</tbody>
</table>

*The sGEP/sMICA levels examined by ELISA were modeled as categorical variables in the analyses. The optimal cutoff value to segment was determined by maximizing the Youden index.

**DISCUSSION**

As a hallmark of tumor progression and recurrence, tumors have developed diverse mechanisms to evade the immune system (Hanahan, D and Weinberg, R.A. *Cell*. 2011). Tumor cells have evolved to down-regulate their surface MICA by proteolytic shedding, therefore reducing their susceptibility to NK2GD-mediated NK cytotoxicity (Nausch, N and Cerwenka A. *OncoGene*. 2008). In this study, it was shown that GEP down-regulated MICA levels on HCC cell surface, therefore rendering GEP-expressing cells less susceptible to NK cytotoxicity. Besides, GEP over-expression promoted the production of soluble MICA (sMICA) from HCC cells. sMICA released from tumor cell surface can not only block the NK2GD-binding site for other NK2GD ligands, but also suppress NK2GD expression on NK cells (Nausch, N and Cerwenka A. *OncoGene*. 2008). Production of sMICA therefore represents one of the mechanisms in tumor immunoevasion (Bauer, S et al. *Science*. 1999; Salih, H R et al. *J Immunol*. 2002). Here, it was also shown that upon co-culture with HCC cells over-expressed with GEP, surface NK2GD on NK cells significantly decreased (FIG. 2D). Hence, GEP might confer HCC cells immunoevasion ability by promoting shedding of surface MICA and promote release of sMICA which perturbs NK cytotoxicity.

prognosis markers for HCC, the association of sGEP and sMICa levels with clinicopathological parameters in HCC patients (n=80) was determined. Here, it was found that sGEP levels significantly correlated with tumor size. Besides, patients with high sGEP and sMICa have poor recurrence-free survival in early and advanced tumor staged patients. Further analysis by Cox regression confirmed that high sGEP and sMICa levels were independent prognostic factors for recurrence-free survival. Therefore, sGEP and sMICa levels can be used as potential prognostic markers for HCC patients.

[0160] Proteolytic cleavage and/or exosome secretion has been reported for shedding of MICA (Sahil, H R et al. J Immunol. 2002; Groh, V et al. Nature. 2002). Matrix metalloproteinases (MMP) 9 and 14 were shown to mediate MICA shedding in various human cancers (Sun, D et al. Cell Biol Int. 2011; Liu, G et al. J Immunol. 2010). MMP9 is produced in a latent form, which requires activation to achieve catalytic activity. GEP was reported in ovarian cancer cell line model to regulate activation of MMP2 (Liu, Y et al. BMC Cancer. 2007), which in turn, was an activator of pro-MMP9 (Toth, M et al. Biochem Biophys Res Commun. 2003). Therefore, GEP might promote shedding of MICA from HCC cells by regulating MMP2 activation. Besides, it was previously found that transcript levels of GEP and MMP14 were significantly correlated in HCC tissues (unpublished data). However, further investigation is needed to clarify the mechanism underlying the cleavage of MICA from GEP-expressing HCC cells.

[0161] In addition to MICA, the unique long 16-binding protein (ULBP) family is also important ligand for NKG2D in human (Cosman, D et al. Immunity. 2001). Of which, ULBP1 was reported to express abundantly in HCC, and the loss of ULBP1 expression was significantly associated with early recurrence of HCC after hepatic resection (Kamimura, H et al. J Hepatol. 2012). However, there is no association between ULBP1 expression and overall survival of HCC patients. Although the loss of ULBP1 expression in poorly-differentiated HCC was shown to be induced by over-expression of proteasomes (Kamimura, H et al. J Hepatol. 2012), the mechanism involved is still unknown. The relationship between GEP and ULBP1 expression in HCC would be an intriguing area to be explored.

[0162] Up-regulation of HLA-E was suggested to represent a mechanism of tumor escape from NK cytotoxicity in ovarian cancer and melanoma (Malmberg, K et al. J Clin Invest. 2002; Speiser, D E et al. J Exp Med. 1999). HLA-E mRNA was reported to be up-regulated in HCC tissues when compared with their adjacent non-tumor counterparts (Chen, A et al. Neoplasma. 2011). Besides, HLA-E polymorphism was associated with risk of hepatitis B or HCC (Zhang, J et al. Immunogenetics. 2012). However, the role of HLA-E in HCC pathogenesis and the cell populations over-expressing HLA-E have not been elucidated in HCC yet. Here, it is shown that GEP expression up-regulated HCC cells’ surface expression of HLA-E. HLA-E might therefore play role in HCC pathogenesis by promoting immunoevasion ability of GEP-expressing cells.

[0163] All patents, patent applications, provisional applications, and publications referred to or cited herein are incorporated by reference in their entirety, including all figures and tables, to the extent they are not inconsistent with the explicit teachings of this specification.

[0164] It should be understood that the examples and embodiments described herein are for illustrative purposes only and that various modifications or changes in light thereof will be suggested to persons skilled in the art and are to be included within the spirit and purview of this application and the scope of the appended claims. In addition, any elements or limitations of any invention or embodiment thereof disclosed herein can be combined with any and/or all other elements or limitations (individually or in any combination) or any other invention or embodiment thereof disclosed herein, and all such combinations are contemplated with the scope of the invention without limitation thereto.

REFERENCES


ctgcgcccc aggaacgccg agtggagcgc aggcagaaca tgtggacact ggtgagcttg 240
gtggcctaaa cagcagggct ggctggctgg aagcggctgc cagatgctca gtctgacct 300
gctgctgcc gcctgagacc cgagaggccg agctacaggct gctgcagctcc cctctctggac 360
aataagggcc caacactgag cagggcatcg ggtcgcgctct gcaggtctga tgcccaacctgc 420
tctgagggcc aacctgggc attaagggct ccagaagaact cagctgctgcg cccccctccaa 480
agaagcgcttg catgggggga tgtgcaatcc tgtgcgcccc cggggcttccaa ctcagctgca 540
gacgaggggat cttgatccaa aagatcagat gaaatctcgt tcagtcgctat ccagctgacct 600
gatagctgaa cagctcttcgc gaaacttacct caagggctgtt tgatactggtg atgtcccttg 660
gggtgctgc cctaggcctg gttcttcgtcg tgaggaacta cgggcttgat gctgggtgcc 720
ggctggcct tcagaggttc ctccatactgc gagaactgac ccagcggcag ccaccaacctgc 780
gacaagagcc tcctggccag gaggacactc aggaagcttg ccaggtcgtgg cagctgctgcg 840
tgctgagag caggtcggcg gtagctccgt ggtctcatcc gctgtgcttg gcacagtgcc 900
agattgcttg gctgctccat gcccaagccg aacagctgct gcctgctcc gcagctgacctg 960
ccccaagcc ctcctggctca cagctctctc agtacaacct ctcctcaagaa gcacattacc 1020
cagaaacctc tccatagct gctgcggccag cagctgggag atgtgaaatt tgacatgagg 1080
gctggctgc ccatatggct taccattcgt ccgactagct gcgagaggttg ggtgggtgcg 1140
cctttccaccc agggctgttg tcgtagagcc cacaactacct gcgtctgcccc cgggacttaag 1200
tgtgagatgc lagagggctat ctcgctacag cggcccaacc aagttggctg gatgcgagaa 1260
gcccaagctc ctctgagctg gcaagacacc caagccctga agagagtagt ccacctgtgc 1320
aagtgcaaca gctggcccttc ctcgtatacc tgtgcaaccc tcaagcttgg gcagggggcc 1380
tgctgagctgc ttcgagatcc tgtcgcgctgc tggagacgcc aagcaacctgct ccccaaggcc 1440
tccatgcgtg tagctggggg cagctagctg cagagagctg gcgcagtgagg 1500
aagatgctgg cccggcggggt ttccttaccc caccatcaag aacagctgctg tgaacacacg 1560
acagactgctg cgggctggcag gcaggtcctg ccagacgttg gtgaggagtg ccagctgctgcg 1620
cagtgcggtcc atgtctgtcc gtggagagat gcacagactt gcggccgctgc cttgcacacc 1680
tgacagtgct agcgctgtgct tcgtgagag cagctgctcc tgtgcaaccc tcaagcttgg 1740
tgctgctgcc gccttcagcc gggtggagct gtgtggagct gcgagagact gacaactctgcg 1800
cagcattacc aagcagctgtg cgcagaccc cgcagacgcgg ggccgtcttg ttcctacggc 1860
cagggcttggt ctggagcgact gcgcgcttgg gcgctgtcttc ccggctgcag tggccagccg 1920
aggggcctgc agtgtttcgg cggggacgct ccaggctgggg aacccctctt tcgagccacc 1980
gctttccgg aagttggctg ctgacagacc tgcagaccc gtgtgagtc gggagccaccg 2040
tcgagaggtg ctcctgtctg agcccttctc acagagctcc cccatccaaa ttcctcttgg 2100
acccacatg cagctgctgc ttcacgaggg agtggggcgc tcaaatag ccgctccctgc 2160
tccagaggg ggagatctg aagccactg ccaagagctgc acctccctcc cggcggtctg 2220
acaggtctgg ccagctgttt ttctctctcc cccagagtgg ccaggggttg ttcgtggtctg ggcctggtg 2280
gtcttcagataa atgtttgaca ctctcaaaaa aaaaaaaaaa aaa 2323
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 2

Met Trp Thr Leu Val Ser Trp Val Ala Leu Thr Ala Gly Leu Val Ala
1  5  10  15
Gly Thr Arg Cys Pro Asp Gly Gln Phe Cys Pro Val Ala Cys Cys Leu
20  25  30
Asp Pro Gly Gly Ala Ser Tyr Ser Cys Arg Pro Leu Leu Asp Lys
35  40  45
Trp Pro Thr Leu Ser Arg His Leu Gly Gln Pro Cys Gln Val Asp
50  55  60
Ala His Cys Ser Ala Gly His Ser Cys Ile Phe Thr Val Ser Gly Thr
65  70  75  80
Ser Ser Cys Cys Pro Phe Pro Glu Ala Val Ala Cys Gly Asp Gly His
85  90  95
His Cys Cys Pro Arg Gly Phe His Cys Ser Ala Asp Gly Arg Ser Cys
100 105  110
Phe Gln Arg Ser Gly Asn Ser Val Gly Ala Ile Gln Cys Pro Asp
115 120  125
Ser Gln Phe Glu Cys Pro Asp Phe Ser Thr Cys Val Met Val Asp
130 135  140
Gly Ser Trp Gly Cys Pro Met Pro Gln Ala Ser Cys Cys Glu Asp
145 150 155  160
Arg Val His Cys Cys Pro His Gly Ala Phe Cys Asp Leu Val His Thr
165 170  175
Arg Cys Ile Thr Pro Thr Gly Thr His Pro Leu Ala Lys Leu Leu Pro
180 185  190
Ala Gln Arg Thr Asn Arg Ala Val Ala Leu Ser Ser Val Met Cys
195 200  205
Pro Asp Ala Arg Ser Arg Cys Pro Asp Gly Ser Thr Cys Cys Glu Leu
210 215  220
Pro Ser Gly Lys Tyr Gly Cys Cys Pro Met Pro Asn Ala Thr Cys Cys
225 230  235  240
Ser Asp His Leu His Cys Cys Pro Gln Asp Thr Val Cys Asp Leu Ile
245 250  255
Gln Ser Lys Cys Leu Ser Lys Glu Asn Ala Thr Asp Leu Leu Thr
260 265  270
Lys Leu Pro Ala His Thr Val Gly Asp Val Lys Cys Asp Met Glu Val
275 280  285
Ser Cys Pro Asp Gly Tyr Thr Cys Arg Leu Glu Ser Gly Ala Trp
290 295  300
Gly Cys Cys Pro Phe Thr Gln Ala Val Cys Cys Glu Asp His Ile His
305 310  315  320
Cys Cys Pro Ala Gly Phe Thr Cys Asp Thr Glu Lys Gly Thr Cys Glu
325 330  335
Gln Gly Pro His Gln Val Pro Trp Met Glu Lys Ala Pro Ala His Leu
340 345  350
Ser Leu Pro Asp Pro Gln Ala Leu Lys Arg Asp Val Pro Cys Asp Asn
355 360  365
Val Ser Ser Cys Pro Ser Ser Asp Thr Cys Cys Glu Leu Thr Ser Gly
Glu Trp Gly Cys Cys Pro Ile Pro Glu Ala Val Cys Cys Ser Asp His
385 390 395 400
Gln His Cys Cys Pro Gin Gly Tyr Thr Cys Val Ala Glu Gly Gin Cys
405 410 415
Gln Arg Gly Ser Glu Ile Val Ala Gly Leu Glu Lys Met Pro Ala Arg
420 425 430
Arg Ala Ser Leu Ser His Pro Arg Asp Ile Glu Cys Asp Gin His Thr
435 440 445
Ser Cys Pro Val Gly Gin Thr Cys Pro Ser Leu Gly Gly Ser Trp
450 455 460
Ala Cys Cys Gln Leu Pro His Ala Val Cys Cys Glu Asp Arg Gin His
465 470 475 480
Cys Cys Pro Ala Gly Tyr Thr Cys Asn Val Lys Ala Arg Ser Cys Glu
485 490 495
Lys Glu Val Val Ser Ala Gln Pro Ala Thr Phe Leu Ala Arg Ser Pro
500 505 510
His Val Gly Val Lys Asp Val Glu Cys Gly Glu Gly His Phe Cys His
515 520 525
Asp Asn Gln Thr Cys Cys Arg Asp Asn Arg Gin Gly Trp Ala Cys Cys
530 535 540
Pro Tyr Arg Gin Gly Val Cys Cys Ala Asp Arg Arg His Cys Cys Pro
545 550 555 560
Ala Gly Phe Arg Cys Ala Ala Arg Gly Thr Lys Cys Leu Arg Arg Glu
565 570 575
Ala Pro Arg Trp Asp Ala Pro Leu Arg Asp Pro Ala Leu Arg Gin Leu
580 585 590
Leu

<210> SEQ_ID NO 3
<211> LENGTH: 16
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 3

Pro Arg Trp Asp Ala Pro Leu Arg Asp Pro Ala Leu Arg Gin Leu Leu
1  5
10  15

<210> SEQ_ID NO 4
<211> LENGTH: 48
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 4

Cys Cys Gly Cys Gly Cys Thr Gly Gly Gly Ala Cys Gly Cys Cys Cys
1  5  10  15
Cys Thr Thr Thr Gly Ala Gly Gly Ala Cys Cys Cys Ala Gly Cys
20  25
30
Cys Thr Thr Thr Gly Ala Gly Ala Cys Ala Gly Cys Thr Gly Gly Thr Gly
35  40  45

<210> SEQ_ID NO 5
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens
<400> SEQUENCE: 5
His Leu Ser Leu Pro Asp Pro Gin Ala Leu Lys Arg Asp Val Pro
1        5        10        15

<210> SEQ ID NO 6
<211> LENGTH: 45
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 6
Cys Ala Cys Cys Cys Thr Cys Ala Gly Cys Thr Gly Cys Ala Gly
1        5        10        15
 Ala Cys Cys Ala Cys Ala Ala Gly Cys Cys Thr Thr Gly Ala Ala
20       25       30
 Gly Ala Gly Ala Ala Thr Gly Thr Cys Cys Cys Cys
35       40       45

<210> SEQ ID NO 7
<211> LENGTH: 20
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 7
Arg Arg Glu Ala Pro Arg Trp Asp Ala Pro Leu Arg Asp Pro Ala Leu
1        5        10        15
 Arg Gin Leu Leu
20

<210> SEQ ID NO 8
<211> LENGTH: 60
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 8
Cys Gly Cys Ala Gly Gly Ala Gly Gly Cys Cys Cys Gly Cys
1        5        10        15
 Gly Cys Thr Gly Gly Ala Cys Gly Cys Cys Cys Thr Thr
20       25       30
 Gly Ala Gly Gly Ala Cys Cys Cys Cys Cys Cys Cys Thr Thr
35       40       45
 Ala Gly Ala Cys Ala Gly Cys Thr Gly Cys Thr Cys
50       55       60

<210> SEQ ID NO 9
<211> LENGTH: 27
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 9
Gin Gly Pro His Gin Val Pro Trp Met Glu Ala Pro Ala His Leu
1        5        10        15
 Ser Leu Pro Asp Pro Gin Ala Leu Lys Arg Asp
20       25

<210> SEQ ID NO 10
<211> LENGTH: 81
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<400> SEQUENCE: 10

ccagcccccccc aaccagtgcc ctggagttgg sggggccccgg ctcagctaca aagttggcagc 60
ccacaagctg tgaagagaga t 81

<210> SEQ ID NO: 11
<211> LENGTH: 17
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 11

Met Trp Thr Leu Val Ser Trp Val Ala Leu Thr Ala Gly Leu Val Ala
1   5   10  15
Gly

<210> SEQ ID NO: 12
<211> LENGTH: 51
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 12

atgagagcccc tgggtgctg cgggctttgg ccagccccgg ggtgagttgg a 51

<210> SEQ ID NO: 13
<211> LENGTH: 33
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 13

Thr Arg Cys Pro Asp Gly Gln Phe Cys Pro Val Ala Cys Cys Leu Asp
1   5   10  15
Pro Gly Ala Ser Tyr Ser Cys Cys Arg Pro Leu Leu Asp Lys Trp
20  25  30
Pro

<210> SEQ ID NO: 14
<211> LENGTH: 120
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 14

aaggtcagtc aatcgggctg ccttcgctgg ggtgctgcc cgggctttgg 60
agatagcctgcc ggtgagttgg aatactgcac aagttggcagc 120

<210> SEQ ID NO: 15
<211> LENGTH: 10
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 15

Gln Arg Ser Gly Arg Arg Ser Gly Arg Ser Val Gly
1  5

<210> SEQ ID NO: 16
<211> LENGTH: 27
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 16
-continued

cacaagctcag gtaacaactc cgtgggpt 27

<210> SEQ ID NO 17
<211> LENGTH: 26
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 17

Thr Pro Thr Gly Thr His Pro Leu Ala Lys Lys Leu Pro Ala Gln Arg
1    5     10    15
Thr Arg Ala Val Ala Leu Ser Ser Ser
20    25

<210> SEQ ID NO 18
<211> LENGTH: 78
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 18

acacccacgg gcaccacacc cctggccaaag aagctccctg cccagagac taaccaggca 60
gcggccttt gcagcctcg 78

<210> SEQ ID NO 19
<211> LENGTH: 18
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 19

Lys Glu Aem Ala Thr Thr Asp Leu Leu Thr Lys Leu Pro Ala His Thr
1    5     10    15
Val Gly

<210> SEQ ID NO 20
<211> LENGTH: 57
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 20
tccagagaga acgtaaacc gcaccctctc actaaagctgc tgcgcacac agtcggg 57

<210> SEQ ID NO 21
<211> LENGTH: 24
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 21

Arg Gly Ser Glu Ile Val Ala Gly Leu Glu Lys Met Pro Ala Arg Arg
1    5     10    15
Ala Ser Leu Ser His Pro Arg Asp
20

<210> SEQ ID NO 22
<211> LENGTH: 72
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 22
cgagagcg agatcgggg tggactgcag aagatgcctg cccgcgaggg ttcctatcc 60
cacccccacag ac 72
We claim:

1. A method of treating liver cancer, comprising administering to a subject that has liver cancer an effective amount of an agent that promotes natural killer (NK) cell activity.

2. The method according to claim 1, wherein the agent inhibits the activity of granulin-epithelin precursor (GEP).

3. The method according to claim 2, wherein the agent that inhibits the activity of GEP is an anti-GEP antibody.

4. The method according to claim 3, wherein the anti-GEP antibody is a monoclonal antibody.

5. The method according to claim 3, wherein the anti-GEP antibody is a polyclonal antibody.

6. The method of claim 2, wherein the agent is a siRNA or shRNA against GEP mRNA.

7. The method according to claim 1, comprising administering an effective amount of NK cells.

8. The method according to claim 1, wherein the agent that promotes NK cell activity is selected from IL-15, IL-12, pectin, IL-2, IFN-gamma, and IL-21.

9. The method according to claim 1, wherein the subject is a human.

10. A method of preventing recurrence of or treating liver cancer in a subject, wherein the method comprises administering to a subject an effective amount of an agent that inhibits the expression or activity of granulin-epithelin precursor (GEP), wherein the subject had surgical resection of a primary liver tumor, underwent hepatectomy, and/or had liver transplantation.

11. The method according to claim 10, comprising administering an agent that inhibits the activity of GEP.

12. The method according to claim 10, wherein the agent that inhibits the activity of GEP is an anti-GEP antibody.

13. The method according to claim 10, wherein the anti-GEP antibody is a monoclonal antibody.

14. The method according to claim 10, wherein the anti-GEP antibody is a polyclonal antibody.

15. The method according to claim 10, further comprising administering an effective amount of NK cells.

16. The method according to claim 10, further comprising administering an effective amount of an agent that promotes NK cell activity.

17. The method according to claim 16, wherein the agent that promotes NK cell activity is selected from IL-15, IL-12, pectin, IFN-gamma, IL-2, and IL-21.

18. The method according to claim 10, wherein the subject is a human.

19. A method of treating liver cancer, comprising administering to a subject that has liver cancer an effective amount of an agent that increases MHC class I chain-related molecule A (MICA) expression on liver cancer cells.

20. The method according to claim 19, wherein the agent inhibits the activity of granulin-epithelin precursor (GEP).

* * * * *